Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Nudelman

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Nature Clinical Practice. Rheumatology|April 17, 2008
Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritisMarcia L Moss, Liora Sklair-Tavron, Raphael Nudelman
Combinatorial Chemistry & High Throughput Screening|December 18, 2009
Fluorescent substrates useful as high-throughput screening tools for ADAM9Marcia L Moss, Fred H Rasmussen, Raphael Nudelman, et al.
Environmental and Molecular Mutagenesis|August 24, 2024
Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potentialJennifer Cheung, Krista Dobo, Shaofei Zhang, et al.
Cell|May 23, 2002
OxyR: a molecular code for redox-related signalingSung Oog Kim, Kunal Merchant, Raphael Nudelman, et al.
Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.
Environmental and Molecular Mutagenesis|May 9, 2025
Using N-Nitrosodiethanolamine (NDELA) and N-Nitrosopiperidine (NPIP) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency-Based Acceptable Intakes for NDSRIs Lacking Robust Carcinogenicity DataJason M Roper, Troy R Griffin, George E Johnson, et al.
Regulatory Toxicology and Pharmacology : RTP|December 11, 2024
Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakesDavid J Ponting, Andreas Czich, Susan P Felter, et al.
Regulatory Toxicology and Pharmacology : RTP|September 2, 2023
Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessmentsAlex N Cayley, Robert S Foster, Alessandro Brigo, et al.
Journal of Medicinal Chemistry|May 26, 2006
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depressionOren M Becker, Dale S Dhanoa, Yael Marantz, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2019
Qualification of impurities based on metabolite dataLars Weidolf, Thomas Andersson, Joel P Bercu, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Nature Clinical Practice. Rheumatology|April 17, 2008
Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritisMarcia L Moss, Liora Sklair-Tavron, Raphael Nudelman
Combinatorial Chemistry & High Throughput Screening|December 18, 2009
Fluorescent substrates useful as high-throughput screening tools for ADAM9Marcia L Moss, Fred H Rasmussen, Raphael Nudelman, et al.
Environmental and Molecular Mutagenesis|August 24, 2024
Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potentialJennifer Cheung, Krista Dobo, Shaofei Zhang, et al.
Cell|May 23, 2002
OxyR: a molecular code for redox-related signalingSung Oog Kim, Kunal Merchant, Raphael Nudelman, et al.
Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.
Environmental and Molecular Mutagenesis|May 9, 2025
Using N-Nitrosodiethanolamine (NDELA) and N-Nitrosopiperidine (NPIP) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency-Based Acceptable Intakes for NDSRIs Lacking Robust Carcinogenicity DataJason M Roper, Troy R Griffin, George E Johnson, et al.
Regulatory Toxicology and Pharmacology : RTP|December 11, 2024
Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakesDavid J Ponting, Andreas Czich, Susan P Felter, et al.
Regulatory Toxicology and Pharmacology : RTP|September 2, 2023
Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessmentsAlex N Cayley, Robert S Foster, Alessandro Brigo, et al.
Journal of Medicinal Chemistry|May 26, 2006
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depressionOren M Becker, Dale S Dhanoa, Yael Marantz, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2019
Qualification of impurities based on metabolite dataLars Weidolf, Thomas Andersson, Joel P Bercu, et al.
Pageof 2